ZyVersa Therapeutics, Inc.
ZVSA
$0.7899
-$0.0111-1.39%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.71M | 8.11M | 9.99M | 11.21M | 13.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.63M | 10.26M | 12.66M | 14.42M | 17.83M |
| Operating Income | -9.63M | -10.26M | -12.66M | -14.42M | -17.83M |
| Income Before Tax | -21.92M | -22.42M | -105.99M | -107.75M | -99.24M |
| Income Tax Expenses | -586.40K | -586.90K | -8.41M | -9.46M | -9.60M |
| Earnings from Continuing Operations | -21.33 | -21.83 | -97.58 | -98.30 | -89.64 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.33M | -21.83M | -97.58M | -98.30M | -89.64M |
| EBIT | -9.63M | -10.26M | -12.66M | -14.42M | -17.83M |
| EBITDA | -9.62M | -10.25M | -12.64M | -14.41M | -17.82M |
| EPS Basic | -69.90 | -97.65 | -1.79K | -1.92K | -1.86K |
| Normalized Basic EPS | -11.38 | -28.51 | -89.55 | -196.73 | -191.80 |
| EPS Diluted | -69.90 | -97.65 | -1.79K | -1.92K | -1.86K |
| Normalized Diluted EPS | -11.38 | -28.51 | -89.55 | -196.73 | -191.80 |
| Average Basic Shares Outstanding | 2.67M | 1.78M | 995.60K | 398.10K | 91.71M |
| Average Diluted Shares Outstanding | 2.67M | 1.78M | 995.60K | 398.10K | 91.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
